tiprankstipranks
Advertisement
Advertisement
Maze Therapeutics Advances MZE782 Phase 2 PKU Trial, Setting Up a New Catalyst for MAZE Investors
PremiumCompany AnnouncementsMaze Therapeutics Advances MZE782 Phase 2 PKU Trial, Setting Up a New Catalyst for MAZE Investors
2M ago
Analyst Reaffirms Buy on Maze with Unchanged $110 Price Target, Citing Strong HORIZON Data and Favorable Risk-Reward
Premium
Ratings
Analyst Reaffirms Buy on Maze with Unchanged $110 Price Target, Citing Strong HORIZON Data and Favorable Risk-Reward
3M ago
Maze Therapeutics Shareholders Elect Directors, Ratify Auditor
Premium
Company Announcements
Maze Therapeutics Shareholders Elect Directors, Ratify Auditor
3M ago
Maze Therapeutics prices $150 million equity offering
PremiumCompany AnnouncementsMaze Therapeutics prices $150 million equity offering
5M ago
Maze Therapeutics priced offering of 5.54M shares of common stock at $23.50
Premium
The Fly
Maze Therapeutics priced offering of 5.54M shares of common stock at $23.50
5M ago
Maze Therapeutics price target lowered to $64 from $68 at Truist
Premium
The Fly
Maze Therapeutics price target lowered to $64 from $68 at Truist
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100